Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

Asahi Glass to Unify Subsidiaries

Photonics.com
Jan 2018
TOKYO, Jan. 25, 2018 — Glass manufacturer Asahi Glass Co. Ltd. will integrate its bioscience business, unifying its bioscience contract development and manufacturing organization (CDMO) subsidiaries under the AGC Biologics name.

The company has set up its center of operations in Seattle and appointed Gustavo Mahler, CEO of CMC Biologics, as head of the integrated bioscience operations. The corporate names of CMC Biologics and Biomeva GmbH will also be changed to AGC Biologics.

AGC made its first foray into bioscience-related business in 1985 and launched its first contract pharmaceutical manufacturing business in 2000 by operating a microorganism-based CDMO that operated mostly in Japan. AGC acquired Biomeva in 2016 and acquired CMC Biologics in 2017, establishing a three-branch structure for the group's bioscience operations. AGC operated mainly in Japan and other countries in Asia; Biomeva mainly in Europe; and CMC Biologics mainly in North and South America and Europe.

Through this current business integration effort, AGC will centralize the core functions at a single location, unifying quality standards and operating methods. This move aims to provide clients with a smooth, consistent interface and high-quality services.


BusinessAsahi GlassAGC BiologiesGustavo MahlerCMC BiologicsBiomevapeoplemergers and acquisitionsAsia-PacificAmericasEurope

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com
x We deliver – right to your inbox. Subscribe FREE to our newsletters.